ACON vs. NIVF, BTTX, AVHIU, AONC, ARDT, CORBF, LFMDP, NTRA, FMS, and OPCH
Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include NewGenIvf Group (NIVF), Better Therapeutics (BTTX), Achari Ventures Holdings Corp. I (AVHIU), American Oncology Network (AONC), Ardent Health Partners (ARDT), Global Cord Blood (CORBF), LifeMD (LFMDP), Natera (NTRA), Fresenius Medical Care (FMS), and Option Care Health (OPCH). These companies are all part of the "healthcare" industry.
NewGenIvf Group (NASDAQ:NIVF) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership.
NewGenIvf Group has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by company insiders. Comparatively, 22.3% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
NewGenIvf Group has higher earnings, but lower revenue than Aclarion.
In the previous week, NewGenIvf Group had 1 more articles in the media than Aclarion. MarketBeat recorded 5 mentions for NewGenIvf Group and 4 mentions for Aclarion. NewGenIvf Group's average media sentiment score of 0.66 beat Aclarion's score of 0.39 indicating that Aclarion is being referred to more favorably in the news media.
NewGenIvf Group has a net margin of 0.00% compared to NewGenIvf Group's net margin of -10,246.33%. Aclarion's return on equity of 0.00% beat NewGenIvf Group's return on equity.
Aclarion received 1 more outperform votes than NewGenIvf Group when rated by MarketBeat users.
Summary
NewGenIvf Group beats Aclarion on 6 of the 10 factors compared between the two stocks.
Get Aclarion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclarion Competitors List
Related Companies and Tools
Free ACON Stock Alerts